Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer

Detalles Bibliográficos
Autores principales: Beer, Tomasz M, Vogelzang, Nicholas, Bartůňková, Jiřina, Miller, Kurt, Oh, William, Oudard, Stephane, Pandha, Hardev, Sartor, A Oliver, Špíšek, Radek, Toole, Timothy O, Borgstein, Niels G, Gerritsen, Winald R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646109/
http://dx.doi.org/10.1186/2051-1426-3-S2-P164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646109/
http://dx.doi.org/10.1186/2051-1426-3-S2-P164

Ejemplares similares